Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts
- 5 August 2002
- journal article
- research article
- Published by Springer Nature in Nature Genetics
- Vol. 32 (1) , 201-205
- https://doi.org/10.1038/ng946
Abstract
The c-Jun NH2-terminal kinase (JNK) is implicated in the apoptotic response of cells exposed to stress1, but the JNK signal transduction pathway may not act exclusively in apoptosis1. In some studies of tumor cells, JNK has been implicated in signaling cell survival1. The possibility that JNK might mediate a survival signal in tumor cells is consistent with the observation that it is activated in response to some oncogenes, such as the leukemogenic oncogene BCR–ABL, which is created by a reciprocal translocation between human chromosomes 9 and 22 (ref. 2). The BCR-ABL protein activates the JNK signaling pathway in hematopoietic cells and increases transcriptional activity mediated by the transcription factor AP1 (ref. 3). Also, inhibition of c-Jun or JNK prevents BCR–ABL-induced cell transformation in vitro3,4. Although this implicates the JNK signaling pathway in transformation by BCR–ABL, the possible role of JNK in this process is unclear. We find that disruption of the JNK ortholog Mapk8 (also known as Jnk1) in mice causes defective transformation of pre-B cells by BCR–ABL in vitro and in vivo. The Jnk1 protein is required for the survival of the transformed cells in the absence of stromal support. Failure to survive is associated with decreased expression of Bcl2, and the effect of Jnk1 deficiency can be rescued by transgenic expression of Bcl2. Our results show that Jnk1 signals cell survival in transformed B lymphoblasts and suggest that it may contribute to the pathogenesis of some proliferative diseases.Keywords
This publication has 28 references indexed in Scilit:
- Signal Transduction by the JNK Group of MAP KinasesPublished by Elsevier ,2000
- Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding ProteinJournal of Biological Chemistry, 2000
- Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XLThe Journal of Experimental Medicine, 2000
- The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic ActivityThe Journal of Experimental Medicine, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogeneCell, 1995
- Blast crisis in a murine model of chronic myelogenous leukemia.Proceedings of the National Academy of Sciences, 1991
- Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.Proceedings of the National Academy of Sciences, 1991
- In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.Proceedings of the National Academy of Sciences, 1987
- Murine B cell lymphopoiesis in long term cultureJournal of Immunological Methods, 1984